CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)	12 Months Ended
	Sep. 30, 2012		Sep. 30, 2011
Income Statement [Abstract]
License Fees and Royalties	$ 166,803		$ 158,166
Consulting Revenues	0		25,337
TOTAL REVENUES	166,803		183,503
General and Administrative Expenses	404,791		374,676
Research and Development Expenses			16,609
Depreciation	2,280		33,698
LOSS FROM OPERATIONS	(240,268)		(241,480)
OTHER INCOME
Other Income	244,325		83,292
Interest Income	682
OTHER EXPENSES
Interest Expense, net	(97,632)		(103,872)
LOSS BEFORE INCOME TAXES	(92,893)		(262,060)
Income Tax (Note 10)
Net Loss	(92,893)		(262,060)
Net Income/(Loss) attributable to Non-controlling interest	15,604
Net Gain/(Loss) Attributable to AlphaRx Inc. Stockholders	(77,289)		(262,060)
Comprehensive Loss
Net Gain/(Loss)	(92,893)		(262,060)
Translation Adjustment	(315)		(3,726)
Comprehensive Gain/(Loss)	(93,208)		(265,786)
Less: Comprehensive Loss Attributable to Non-Controlling Interests	(63)		(745)
Comprehensive Gain/(Loss) Attributable to AlphaRx Inc. Stockholders Per Share Data	$ (93,271)		$ (266,531)
Net Loss Per Share, basic and diluted	$ (0.0031)		$ (0.014)
Weighted Average Number of Common Shares Outstanding	25,023,148	[1]	18,960,489	[1]

[1] The 2012 and 2011 Weighted Average Number of Common Shares Outstanding was retroactively restated to reflect the 1 for 5 reverse-split on May 29, 2012 when the FINRA approved this transaction.